Nektar Therapeutics (NKTR) — 8-K Filings

All 8-K filings from Nektar Therapeutics. Browse 30 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (30)

Nektar Therapeutics Files 8-K with Exhibits — Apr 20, 2026 Risk: low
On April 20, 2026, Nektar Therapeutics filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
Nektar Therapeutics Files 8-K — Dec 16, 2025 Risk: low
Nektar Therapeutics filed an 8-K on December 16, 2025, to report on various events. The filing includes information related to Regulation FD disclosures, other
8-K Filing — Nov 21, 2025
Nektar Therapeutics Files 8-K — Nov 10, 2025 Risk: low
Nektar Therapeutics filed an 8-K on November 10, 2025, reporting events as of November 8, 2025. The filing primarily concerns Regulation FD disclosures, other e
Nektar Therapeutics Files 8-K on Financials — Nov 6, 2025 Risk: low
Nektar Therapeutics filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
8-K Filing — Sep 18, 2025
Nektar Therapeutics Files 8-K on Financials — Aug 7, 2025 Risk: low
Nektar Therapeutics filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, and including financial statements and exhib
Nektar Therapeutics Files 8-K with Material Agreement — Jul 1, 2025 Risk: medium
On June 30, 2025, Nektar Therapeutics entered into a material definitive agreement. The company also reported other events and filed financial statements and ex
Nektar Therapeutics Sells U.S. Royalty Rights for $400M — Jun 27, 2025 Risk: medium
Nektar Therapeutics announced on June 27, 2025, that it has entered into a definitive agreement to sell its U.S. royalty rights for the drug Rezdiffra to an aff
Nektar Therapeutics Files 8-K Report — Jun 24, 2025 Risk: low
On June 24, 2025, Nektar Therapeutics filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Ex
Nektar Therapeutics Files 8-K — Jun 6, 2025 Risk: low
Nektar Therapeutics filed an 8-K on June 6, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits.
Nektar Therapeutics Files 8-K — Jun 4, 2025 Risk: low
Nektar Therapeutics filed an 8-K on June 4, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it is a s
Nektar Therapeutics Files 8-K on Shareholder Vote Matters — May 28, 2025 Risk: low
Nektar Therapeutics filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of security holders as of May 23, 2025. The filing details the compan
Nektar Therapeutics Files 8-K on Financials — May 8, 2025 Risk: low
Nektar Therapeutics filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and ex
Nektar Therapeutics Faces Delisting Concerns — Apr 4, 2025 Risk: high
Nektar Therapeutics filed an 8-K on April 4, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest
Nektar Therapeutics Files 8-K for Material Agreement — Mar 28, 2025 Risk: medium
Nektar Therapeutics filed an 8-K on March 28, 2025, reporting a material definitive agreement. The filing does not disclose specific details of the agreement, t
Nektar Therapeutics Files 8-K on Financials — Mar 12, 2025 Risk: low
Nektar Therapeutics filed an 8-K on March 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
Nektar Therapeutics Files 8-K Report — Feb 24, 2025 Risk: low
On February 24, 2025, Nektar Therapeutics filed an 8-K report to disclose other events and financial statements. The filing does not contain specific financial
Nektar Therapeutics Files 8-K — Feb 4, 2025 Risk: low
Nektar Therapeutics filed an 8-K on February 4, 2025, reporting other events and financial statements. The filing does not contain specific details on new mater
Nektar Therapeutics Files 8-K on Asset Acquisition/Disposition — Dec 2, 2024 Risk: medium
Nektar Therapeutics filed an 8-K on December 2, 2024, reporting the completion of an acquisition or disposition of assets. The filing also includes financial st
Nektar Therapeutics Files 8-K — Nov 7, 2024 Risk: low
Nektar Therapeutics filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, and including financial statements and exh
Nektar Therapeutics Files 8-K: Material Agreement, Financials — Nov 4, 2024 Risk: medium
Nektar Therapeutics filed an 8-K on November 4, 2024, reporting on events that occurred on November 1, 2024. The filing indicates a material definitive agreemen
Nektar Therapeutics Files 8-K on Financials — Aug 8, 2024 Risk: low
Nektar Therapeutics filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
Nektar Therapeutics Files 8-K on Shareholder Vote — Jun 6, 2024 Risk: low
Nektar Therapeutics filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 5, 2024. The filing does not contain spec
Nektar Therapeutics Files 8-K on Financials — May 9, 2024 Risk: medium
Nektar Therapeutics filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and ex
Nektar Sells Movantik Rights for Up to $100M — Apr 17, 2024 Risk: medium
Nektar Therapeutics announced on April 17, 2024, that it has entered into a definitive agreement to sell its U.S. royalty rights for the blockbuster drug Movant
Nektar Sells Rezvoglar Rights for $10M Upfront — Mar 4, 2024 Risk: medium
Nektar Therapeutics announced on March 4, 2024, that it has entered into a definitive agreement to sell its U.S. commercial rights for the drug rezvoglar to a t
Nektar Therapeutics Files 8-K with Material Agreement — Mar 4, 2024 Risk: medium
Nektar Therapeutics announced on March 4, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity se
Nektar Therapeutics Terminates Material Agreement — Feb 16, 2024 Risk: medium
Nektar Therapeutics filed an 8-K on February 16, 2024, reporting the termination of a material definitive agreement, effective February 12, 2024. The filing ind
NEKTAR THERAPEUTICS Files 8-K on Financial Condition, Reg FD — Jan 10, 2024
NEKTAR THERAPEUTICS filed an 8-K on January 10, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This fili

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX